ALK and non-small cell lung carcinoma: In Canada, the pCODR estimated smaller added clinical benefit of crizotinib of between 0.131 and 0.211 QALYs for ALK+ NSCLC, at an additional cost between $36,548 and $37,387, resulting in an estimate ICER range of $173,570–$285,299 /QALY gained [44].